Related by context. All words. (Click for frequent words.) 72 ZACTIMA 72 Phase #b/#a clinical 71 relapsed MM 71 ongoing Phase 1b 71 placebo controlled Phase III 71 double blinded placebo 71 recurrent NSCLC 70 biliary tract cancer 70 BRIM2 70 CALGB # [002] 69 AVOREN 69 Tarceva TM 69 prospective randomized multicenter 69 Amrubicin 69 phase IIb clinical 69 randomized controlled multicenter 69 randomized Phase IIb 69 Hepatocellular Carcinoma HCC 69 MAGE A3 ASCI 69 relapsed refractory multiple myeloma 68 Phase Ib II 68 ThermoDox R 68 demonstrated antitumor activity 68 Phase IIIb clinical 68 recurrent glioblastoma multiforme 68 multicenter randomized controlled 68 BCIRG 68 placebo controlled clinical 68 HCV SPRINT 68 fosbretabulin 68 double blinded randomized 68 BRIM3 68 multicenter prospective 68 Folfox 68 evaluating mipomersen 68 Xelox 68 multicenter Phase III 68 PI3K/Akt pathway inhibitor 68 Phase IIIb 68 MGd 68 prospective multicenter 68 papillary renal cell carcinoma 68 assessing T DM1 68 Pivotal Phase III 68 YONDELIS 67 treatment naive genotype 67 CHAMPION PCI 67 multicenter multinational 67 NSABP B 67 LHRH receptor positive 67 Phase III randomized controlled 67 registrational Phase 67 trastuzumab DM1 T DM1 67 BRAF inhibitor 67 Genasense ® 67 metastatic HRPC 67 pain palliation 67 randomized Phase 2b 67 Bayer HealthCare Onyx Pharmaceuticals 67 CIMZIA TM certolizumab pegol 67 dosing cohorts 67 Cloretazine ® 67 cisplatin gemcitabine 67 plus gemcitabine 67 Edge STudy 67 phase IIb III 67 blinded randomized placebo controlled 67 trastuzumab Herceptin R 67 Hedgehog Pathway Inhibitor 67 Randomized Phase 67 number NCT# ClinicalTrials.gov 67 Xeloda ® 67 evaluating tivozanib 67 Pivotal Phase 67 prospective nonrandomized 67 Phase Ib IIa 67 metastatic castrate resistant 67 CYT# potent vascular disrupting 67 multicenter Phase II 67 Tanespimycin 67 rALLy clinical trial 67 stage IIIb IV 67 metastatic GIST 67 TMC# C# 66 Phase III multicenter 66 intravenous RSD# 66 Phase Ib clinical 66 dose escalation Phase 66 galiximab 66 Combination REOLYSIN R 66 refractory chronic lymphocytic 66 ToGA 66 sorafenib tablets 66 prospective randomized placebo 66 alvespimycin 66 IMPACT DCM 66 nonmetastatic 66 recurrent metastatic 66 DASISION 66 EVEREST II 66 Prostate AdenoCarcinoma Treatment 66 LUMINATE 66 refractory colorectal cancer 66 Tumor Response 66 nonsmall cell lung cancer 66 bortezomib Velcade R 66 Degarelix 66 forodesine 66 RECORD1 66 FOLOTYN ® 66 receptor tyrosine kinase inhibitor 66 Matrix Phase 2b 66 Hormone Refractory Prostate Cancer 66 Randomized Phase II 66 confirmatory Phase IIIb 66 recurrent GBM 66 multicenter randomized placebo controlled 66 Phase III Pivotal 66 evaluating REVLIMID 66 metastatic renal cell carcinoma 66 ThermoDox ® clinical 66 Deforolimus 66 PROSTVAC ® 66 Completes Patient Enrollment 66 Endovascular Valve Edge 66 ENESTnd 66 HCV RESPOND 2 65 relapsing remitting MS RRMS 65 Carotid Revascularization Endarterectomy vs. 65 Stage IIIb 65 phase IIIb 65 multicenter placebo controlled 65 thalidomide Thalomid 65 myelodysplastic myeloproliferative diseases 65 Evoltra ® 65 Val HeFT 65 oral ridaforolimus 65 Sorafenib HCC Assessment 65 Hsp# Inhibitor 65 dose escalation clinical 65 ACTEMRA TM 65 docetaxel Taxotere ® 65 Phase III placebo controlled 65 docetaxel Taxotere R 65 evaluating satraplatin 65 Ozarelix 65 lymphoid malignancies 65 elacytarabine 65 including eniluracil ADH 65 ALN VSP Phase 65 multicenter clinical 65 phase IIb trial 65 Aflibercept 65 phase Ib clinical 65 CARE HF 65 neratinib 65 tramiprosate Alzhemed TM 65 phase Ib 65 Pemetrexed 65 ROCKET AF 65 GOUT 65 refractory metastatic 65 mg administered orally 65 trastuzumab emtansine T DM1 65 Initiate Phase 65 RE LY 65 anthracycline taxane 65 CALGB 65 Triapine R 65 tumors GIST 65 refractory CLL 65 Hodgkin lymphoma HL 65 sunitinib malate 65 BARACLUDE ® 65 resectable pancreatic cancer 65 Gynecologic Oncology Group 65 Temsirolimus 65 Randomized Double Blind 65 OvaRex ® MAb 65 recurrent glioma 65 NO# [002] 65 Teriflunomide 65 rALLy 65 Initiates Phase III 65 Allovectin 7 65 EURIDIS 65 Phase IIb III 65 metastatic colorectal 65 randomized controlled Phase 65 Metastatic Melanoma 65 Successfully Completes Phase 65 concurrent chemoradiation 65 pertuzumab 65 TO AVOID PREGNANCY WHILE 65 ExTRACT TIMI 65 pegylated liposomal doxorubicin 65 prospective observational 65 Dacogen injection 65 EDEMA3 65 postoperative chemotherapy 65 Velcade bortezomib 65 pancreatic carcinoma 65 phase IIa clinical 65 cancer mCRC 65 Phase 1b clinical trials 65 Advaxis Phase 65 PANVAC VF 65 intravesical infusion therapy 65 Phase III HEAT 65 Clinicaltrials.gov 65 underwent resection 65 RE LY ® 64 Chronic Lymphocytic Leukemia CLL 64 recurrent malignant glioma 64 Cloretazine 64 randomized multicenter Phase III 64 ZYBRESTAT fosbretabulin 64 candidate CRLX# 64 metastatic CRC 64 EXPLORE Xa 64 retinal vein occlusion induced 64 Phase 1a clinical 64 Initiates Phase II 64 smoldering multiple myeloma 64 placebo controlled Phase 64 Xanafide 64 sorafenib Nexavar 64 Targretin capsules 64 melphalan prednisone 64 Randomized Double blind 64 Aryplase 64 Phase 1b clinical 64 Phase III randomized 64 RCW breast cancer 64 R sorafenib tablets 64 multicenter randomized double 64 budesonide foam 64 multicentre randomized 64 crizotinib PF # 64 Acute Decompensated Heart Failure 64 randomized Phase III 64 Phase IIIb study 64 CLARITY study 64 HER2 positive metastatic breast 64 trastuzumab DM1 64 interferon gamma 1b 64 plus dexamethasone 64 R lenalidomide 64 LBH# 64 Daclizumab 64 LUX Lung 64 Virulizin ® 64 MIVI III 64 Randomised 64 Renal Cell Carcinoma RCC 64 Aplidin 64 FOLFOX6 chemotherapy regimen 64 huN# DM1 64 vincristine doxorubicin 64 Fludara ® 64 clevidipine 64 tanespimycin 64 randomized blinded 64 cetuximab Erbitux 64 Prednisone Against Refractory 64 multicenter phase 64 dacarbazine DTIC 64 essential thrombocythemia ET 64 fallopian tube cancers 64 Zybrestat 64 oral deforolimus 64 INCB# [001] 64 kidney urologic 64 Safinamide 64 allogeneic HSCT 64 Patients Treated With 64 lexidronam injection 64 novel VDA molecule 64 malignant pleural mesothelioma 64 phase IIa 64 treatment naïve genotype 64 HDAC Inhibitor 64 paclitaxel Taxol ® 64 unresectable stage 64 sapacitabine CYC# 64 FluCAM arm 64 pediatric malignancies 64 Brentuximab Vedotin SGN 64 INSPIRE Trial Phase III 64 Allovectin 7 ® 64 phase IIb study 64 CUSTOM III 64 controlled multicenter 64 iniparib BSI 64 multiple myeloma MM 64 pan HDAC inhibitor 64 smoldering myeloma 64 Achieves Primary Endpoint 64 metastatic pancreatic 64 EOquin TM 64 patientswith 64 relapsing multiple sclerosis 64 EGFR HER2 64 p# biomarker 64 neoadjuvant treatment 64 COMFORT II 64 paclitaxel Taxol R 64 cediranib 64 Platinol ® cisplatin 64 metastatic renal 64 Neulasta R 64 SPIRIT FIRST 64 CML CP 64 Neoadjuvant 64 radiation sensitizer 63 GATTEX ™ 63 REVIVE Diabetes 63 imetelstat GRN#L 63 phase IIb 63 metastatic neuroendocrine tumors 63 ZOLINZA 63 hepatocellular cancer 63 gastrin analogue TT 63 Pivotal Trial 63 Initiates Phase 2b 63 stage IIIB 63 ELACYT 63 cilengitide 63 evaluating Nexavar 63 MIST II 63 APPRAISE 63 prospective observational studies 63 Cloretazine R 63 Afatinib 63 refractory AML 63 GetGoal Phase III 63 refractory metastatic colorectal cancer 63 Soft Tissue Sarcoma 63 neoadjuvant 63 Gemzar ® 63 ELOXATIN 63 pediatric pontine glioma 63 multicenter Phase 63 NMIBC 63 randomized multicenter 63 ixabepilone 63 Taxotere ® 63 GATTEX ® 63 DEB# 63 Severe Sepsis 63 superficial bladder cancer 63 huC# DM4 63 PSMA ADC 63 recurrent glioblastoma 63 erlotinib Tarceva ® 63 randomized multicenter trial 63 paclitaxel poliglumex 63 Telik logo TELINTRA 63 Multicenter 63 EmbraceAC 63 catheter occlusion 63 acyclovir Lauriad R 63 DCVax ® Brain 63 Zemplar Capsules 63 sorafenib Nexavar ® 63 AVADO 63 follicular lymphoma FL 63 lintuzumab SGN 63 MEK Inhibitor 63 basal cell carcinoma BCC 63 dose escalation phase 63 gemcitabine chemotherapy 63 LymphoStat B TM 63 CAMMS# 63 Pooled Analysis 63 low dose cytarabine 63 antiretroviral naïve 63 evaluating Vectibix 63 Ceflatonin R 63 heavily pretreated 63 gastrointestinal toxicities 63 histologic subtype 63 refractory multiple myeloma 63 IL# PE#QQR 63 LungAlert TM 63 IMiDs ® compound 63 recurrent metastatic ovarian cancer 63 cytokine refractory 63 Triapine 63 CIMZIA ™ 63 dirucotide MBP# 63 pharmacokinetic PK study 63 metastatic renal cell 63 GRN# 63 Study Evaluating 63 5 fluorouracil leucovorin 63 vinca alkaloid 63 BEXXAR Therapeutic Regimen 63 acute promyelocytic leukemia APL 63 prospective multicentre 63 evaluable subjects 63 relapsed myeloma 63 Proellex TM 63 Vidaza ® 63 underwent surgical resection 63 GERD migraine headaches 63 DCVax R Brain 63 pancreatic neuroendocrine tumors 63 KRAS mutations occur 63 evaluating Xcytrin 63 Meets Primary Endpoint 63 myelofibrosis MF 63 Adjuvant Treatment 63 lenalidomide Revlimid R 63 ZACTIMA TM ZD# 63 axitinib 63 atypical Hemolytic Uremic Syndrome 63 randomized #:#:# 63 Cardiotoxicity 63 leukemia AML 63 paclitaxel carboplatin 63 hepatocellular carcinoma HCC 63 metastatic bladder 63 brivanib 63 Cimzia TM 63 vismodegib 63 Phase #b/#a 63 midstage clinical 63 PROSTVAC TM 63 vemurafenib 63 vidofludimus 63 Phase III VISTA 63 Follicular Lymphoma 63 initiate Phase 1b 63 SPRYCEL ® 63 visilizumab 63 ENDEAVOR III 63 histologically confirmed 63 novel oral anticoagulant 63 relapsed multiple myeloma 63 proteasome inhibitor 63 landmark ATHENA 63 metastatic hormone refractory 63 cutaneous T 63 Phase 2b clinical 63 CLARITY TIMI 63 ospemifene 63 IMPACT IMmunotherapy 63 fallopian tube carcinoma 63 SCCHN 63 Vascugel ® 63 Ceplene/IL-2 63 elotuzumab 63 PARTNER Trial 63 Tamibarotene 63 RSD# oral 63 anthracyclines taxanes 63 Archexin 63 Randomized Study 63 paclitaxel cisplatin 63 decitabine 63 satraplatin Phase 63 Prospective Randomized 63 novel emulsion formulation 63 Doxil ® 63 adecatumumab 63 Newly Diagnosed Multiple Myeloma 63 liver resection 63 Prolongs Survival 63 Bezielle 63 BrachySil TM 63 OncoVEX GM CSF 63 initiated Phase Ib 63 COU AA 63 Phase IIb clinical trials 63 bevacizumab Avastin ® 63 gefitinib Iressa 63 sarcoma melanoma 63 MADIT II 63 APEX PD 63 HCD# [002] 63 HIV HCV coinfected 63 Clinical Antipsychotic Trials 62 metastatic malignant 62 evaluating carfilzomib 62 hypoxia activated prodrug 62 induced macular edema 62 dosing cohort 62 enzastaurin 62 Peginterferon alfa 2b 62 T1c 62 Alocrest 62 chemotherapy cisplatin 62 histone deacetylase HDAC inhibitor 62 advanced metastatic renal 62 Heterozygous Familial Hypercholesterolemia 62 mCRC patients 62 RRMS patients 62 Elagolix 62 Sipuleucel T 62 Completes Enrollment 62 histologies 62 alpha antagonist 62 depsipeptide 62 ID NCT# 62 aflibercept VEGF Trap 62 Aplidin R 62 cMET 62 orally administered inhibitor 62 unresectable malignant mesothelioma UMM 62 AKT inhibitor 62 platinum refractory 62 Initiates Clinical Trial 62 standard chemotherapy regimen 62 Chronic lymphocytic leukemia 62 TG MV 62 PROSTVAC VF 62 NEUVENGE 62 dacarbazine chemotherapy 62 nilotinib Tasigna ® 62 completely resected 62 AVASTIN 62 Initiated Phase 62 K ras mutations 62 GEM OS2 62 nonrandomized 62 romidepsin 62 Epratuzumab 62 UPLYSO 62 BARACLUDE R 62 unique alkylating agent 62 FOLFOX4 62 MERLIN TIMI 62 randomized multicentre 62 antibody MAb 62 NSABP C 62 FOLFIRI alone 62 CAPRIE 62 dasatinib Sprycel ® 62 perifosine KRX 62 Vidaza R 62 Initiates Enrollment 62 GSK# [001] 62 OncoVex 62 inhibitor RG# 62 Left Ventricular Dysfunction 62 Augment Injectable 62 phase III ACCLAIM 62 Randomized Phase III 62 Ophena TM 62 HDL Selective Delipidation 62 EchoCRT 62 Prospective Multicenter 62 Cloretazine R VNP#M 62 Cetuximab Erbitux 62 previously untreated follicular 62 GVAX ® 62 EGFR mutation positive 62 CLL SLL 62 Traficet EN 62 Hepatocellular Carcinoma 62 Alequel 62 NCT# ClinicalTrials.gov 62 Waldenstrom macroglobulinemia 62 Phase III AFFIRM 62 stage IIIB IV 62 haematologic 62 dose dose escalation 62 regorafenib 62 Oral Fingolimod 62 Initiate Phase II 62 FDG-PET/CT 62 Phase III ThermoDox 62 metastatic castration resistant 62 NSABP 62 Motesanib 62 cisplatin vinorelbine 62 VICTOR E1 62 comparator arm 62 Pertuzumab 62 ZYBRESTAT TM 62 advanced hepatocellular carcinoma 62 HGS# 62 mitoxantrone plus 62 preclinical efficacy 62 INCB# [003] 62 pediatric acute lymphoblastic 62 Nexavar sorafenib 62 AEG# 62 virus HCV protease inhibitor 62 Panzem R NCD 62 Lenocta 62 Myocardial Infarction Study 62 fidaxomicin Phase 3 62 CTAP# Capsules 62 mRCC 62 Phase III Clinical Trial 62 estramustine 62 ritonavir boosted 62 alfa 2a 62 VNP#M 62 advanced medullary thyroid 62 CLL8 62 Relapsed Multiple Myeloma 62 cell lymphoma CTCL 62 refractory acute myeloid 62 IMC #B 62 opioid naive 62 Telatinib 62 MKC# MT 62 Omacetaxine 62 Hematologic 62 Dacogen decitabine 62 ER CHOP 62 Tesmilifene 62 Trandolapril 62 acetonide FA 62 ORENCIA ® 62 Commences Phase 62 hA# 62 Phase Ib study 62 nab paclitaxel 62 oxaliplatin Eloxatin 62 Acute Myocardial Infarction 62 XL# SAR# 62 blinded randomized 62 VELCADE melphalan 62 Long Lesion 62 castrate resistant prostate cancer 62 Initiates Clinical 62 liposomal formulation 62 immunomodulatory therapy 62 icatibant 62 phase III isavuconazole 62 Group RTOG 62 telaprevir dosing 62 thorough QT 62 Cutaneous T 62 SUCCEED trial 62 Randomized Evaluation 62 SUTENT ® 62 recurrent glioblastoma multiforme GBM 62 CIMZIA TM 62 humanised monoclonal antibody 62 visceral metastases 62 Seliciclib 62 Omnitarg 62 Acute Ischemic Stroke 62 OPT CHF 62 Atypical Hemolytic Uremic Syndrome 62 APTIVUS r 62 gastrointestinal stromal tumors GIST 62 compound INCB# 62 epirubicin cyclophosphamide 62 Ceflatonin 62 Tramiprosate ALZHEMED TM 62 Phase 2b Clinical Trial 62 somatostatin analogue 62 Multiple Ascending Dose 62 ENDEAVOR IV 62 acute PAO 62 riociguat 62 Medullary Thyroid Cancer 62 undergone radical prostatectomy 62 LEUKINE 62 Specifid 62 adjuvant cisplatin 62 Enzastaurin 62 plus dacarbazine 62 symptomatic BPH 62 randomized discontinuation trial 62 ABCSG 62 Pralatrexate 62 Medidur TM FA 62 trabectedin 62 adecatumumab MT# 62 RE MODEL 62 PEGINTRON TM 62 Zevalin consolidation 62 mapatumumab 62 advanced metastatic prostate 62 ANCHOR trial 62 invasive candidiasis 62 Vicinium TM 62 telomerase inhibitor drug 62 PrevOnco ™ 62 Tolvaptan 62 STRIDE PD 62 ABSORB trial 62 RAPTIVA 62 Renal Cell Carcinoma 62 pancreatic islet cell 62 PDX pralatrexate 62 CCX# 62 APEX AMI trial 62 Multiple Myeloma MM 62 Demonstrates Positive 62 MEND CABG 62 relapsed mantle 62 mertansine 61 Romidepsin 61 FOLFOX6 61 trastuzumab Herceptin ® 61 null responder 61 alkylating agent 61 sunitinib Sutent 61 ADVEXIN clinical 61 hepatitis C HCV 61 ASCO GI 61 anastrazole 61 MGN# 61 lung pancreatic 61 active comparator 61 Phase III metastatic melanoma 61 radiochemotherapy 61 GW# [003] 61 eritoran 61 eribulin mesylate 61 PERSEUS 61 CAELYX 61 GEM OS1 61 Estybon ™ 61 Intervention Effectiveness 61 Unstable Angina 61 gemcitabine carboplatin 61 viral kinetic 61 pegylated interferon alpha 61 SORT OUT III 61 Free Survival PFS 61 #:# randomization 61 multicentre randomized controlled 61 ICON7 61 SPEAR Study 61 pretransplant 61 unresectable HCC 61 Glufosfamide 61 Ganite ® 61 untreated metastatic melanoma 61 RELOVAIR ™ 61 Dapagliflozin 61 Pivotal Study 61 monoclonal antibody conjugated 61 XL# XL# XL# 61 Tykerb lapatinib 61 Actimmune ® 61 RhuDex R 61 acute myeloid 61 VEGFR2 inhibitor 61 OVATURE 61 TASKi2 61 LibiGel Phase III 61 HuMax EGFr 61 systemic anaplastic large 61 Raloxifene Evaluation MORE 61 Phase III Clinical Trials 61 PEG SN# 61 PrevOnco 61 Trial Evaluating 61 XIENCE V Stent System 61 recurrent colorectal cancer 61 multicentre prospective 61 Voreloxin 61 cetuximab Erbitux R 61 BRAF mutated 61 PD LID 61 Cell Lymphoma 61 naïve HCV 61 mg/m2 dose 61 FAME Study 61 infusional 5-FU/LV 61 IV NSCLC 61 Myocet 61 Canvaxin TM 61 Phase IIB 61 aflibercept 61 Recurrent Glioblastoma 61 rALLy trial 61 ancrod 61 IgG1 monoclonal antibody 61 AIR CF1 61 retrospective cohort 61 somatostatin analog 61 Systemic Sclerosis 61 midstage trials 61 familial amyloidotic polyneuropathy FAP 61 Delcath Phase III 61 TELCYTA 61 multicenter randomized 61 Pafuramidine 61 pharmacogenomic translational research 61 Irinotecan 61 systemic RNAi therapeutic 61 AML MDS 61 Gastrointestinal Stromal Tumors 61 ARCOXIA 61 non nucleoside inhibitor 61 Quinamed 61 L BLP# 61 ACUITY trial 61 NCT# 61 PROVENGE ® 61 genotypic resistance 61 Active Ulcerative Colitis 61 Neulasta ® 61 Cimzia ® certolizumab pegol 61 severe hypercholesterolemia 61 Presents Preclinical 61 rituximab Rituxan 61 achieved CCyR 61 Surgical resection 61 Pirfenidone 61 Phase #/#a trial 61 trials RCTs 61 TRANSFORMS 61 Fx #A 61 Vectibix panitumumab 61 myelofibrosis polycythemia vera 61 doxorubicin docetaxel 61 Phase 2a clinical 61 YERVOY 61 Multicenter Randomized 61 omacetaxine mepesuccinate 61 oral FTY# 61 Recurrent Chest Wall 61 Temodar ® 61 deep venous thromboses 61 APTIVUS R 61 Placebo controlled 61 overactive bladder syndrome 61 KRN# 61 Naive Patients 61 systemic ALCL 61 GAMMAGARD 61 LymphoStat B belimumab 61 anticancer compound 61 topoisomerase II inhibitor 61 ONCONASE R 61 sNDA submission 61 hyaluronidase enzyme 61 Malignant Melanoma 61 Gleevec resistant 61 TORISEL 61 RANK Ligand inhibitor 61 Picoplatin Efficacy After 61 adjuvant colon cancer 61 Acute myeloid leukemia AML 61 YONDELIS R 61 doxorubicin cyclophosphamide 61 AIR2 Trial 61 PROTECT AF 61 carcinoma HCC 61 colorectal carcinoma 61 mTOR inhibitor 61 registrational 61 CANCIDAS 61 nucleotide analogue 61 LEP ETU 61 oral rivaroxaban 61 Phase IIa trials 61 TACI Ig 61 placebo controlled randomized 61 Granted Orphan Drug 61 locoregional 61 Pegylated Interferon 61 abiraterone acetate 61 ug dose 61 Digital Mammographic Imaging 61 darinaparsin ZIO 61 ponatinib 61 TRISENOX 61 label multicenter 61 prospective multicenter study 61 Dasatinib 61 REVLIMID lenalidomide 61 Azedra 61 metastatic androgen independent 61 deforolimus 61 eosinophilic asthma 61 squamous histology 61 EGS# 61 SABCS 61 refractory NSCLC 61 oral picoplatin 61 Novel Oral 61 Virologic 61 resected pancreatic cancer 61 dose cohort 61 Coronary Artery Bypass Graft 61 radiolabeled TM# 61 Decitabine 61 SCH # 61 Improves Outcomes 61 Advagraf 61 dasatinib Sprycel 61 immunotherapeutic vaccine 61 CALERIE 61 locoregional recurrence 61 PKC# 61 G#DT 61 investigational protease inhibitor 61 ADVEXIN therapy 61 prospective multicenter randomized 61 Phase 1b 61 CHOP chemotherapy 61 PHX# 61 decompensated liver disease 61 non squamous NSCLC 61 Accelerated Partial Breast Irradiation 61 BCR ABL inhibitor 61 Phase #/#a 61 www.ClinicalTrials.gov 61 IIa trials 61 AFRS TM 61 multi kinase inhibitor 61 ASPIRE HIGHER 61 Annamycin 61 Subgroup analysis 61 IMA# 61 fistulizing Crohn disease 61 Ambrisentan 61 Diabetic Foot Ulcer 61 paclitaxel eluting stents 61 ADVANCE PD 61 non squamous 61 Proxinium TM 61 toenail onychomycosis 61 ® cetuximab 61 Histological 61 Golimumab 61 TTF Therapy 61 registrational trial 61 lumiliximab 61 AA Amyloidosis 61 Phase 2b study 61 PRECiSE 61 oral Hycamtin 61 bortezomib Velcade 61 Akt inhibitor 61 refractory indolent non 61 TLK# 61 Phase III Psoriasis 61 TKB# 61 INTEGRILIN R 61 Phase III confirmatory 61 fluvastatin 61 Advanced Renal Cell 61 squamous non 61 headache nasopharyngitis 61 Begins Dosing 61 pomalidomide 61 dacarbazine 61 prognostic variables 61 FOLFIRI chemotherapy 61 CRLX# 61 Metastatic Colorectal Cancer 61 diagnosed GBM 61 Trastuzumab DM1 61 placebo dexamethasone 61 Thalomid ® 61 Kahalalide F 61 TYKERB 61 glufosfamide 61 tumor histology 61 vinorelbine tartrate 61 polycythemia vera PV 61 Pegylated Liposomal Doxorubicin 61 Myelodysplastic Syndrome MDS 61 TORISEL TM 61 intravenous methylnaltrexone 61 Juvenile Idiopathic Arthritis 61 histone deacetylase inhibitor 61 dose cohorts 61 Microplasmin 61 azilsartan medoxomil 61 ANTEGREN 61 PEG INTRON R 61 #I TM# 61 unresectable Stage III 61 AVERROES 60 CINTREDEKIN BESUDOTOX 60 TELINTRA R 60 antiretroviral naive 60 NATRECOR R 60 novel histone deacetylase 60 telomerase therapeutic 60 candidemia 60 Vascular Disrupting Agent 60 cutaneous T cell 60 IIb clinical trial 60 OHR/AVR# 60 hormone refractory metastatic prostate 60 class anticancer quinolone 60 Screening Trial DMIST 60 Clinical Trial Results 60 5 FU leucovorin 60 Multicenter Phase 60 Aurora Kinase 60 pT2 60 IMiDs ®